CN108969794A - A kind of wound repair and oral care liquid dressing and preparation method thereof - Google Patents
A kind of wound repair and oral care liquid dressing and preparation method thereof Download PDFInfo
- Publication number
- CN108969794A CN108969794A CN201810838864.9A CN201810838864A CN108969794A CN 108969794 A CN108969794 A CN 108969794A CN 201810838864 A CN201810838864 A CN 201810838864A CN 108969794 A CN108969794 A CN 108969794A
- Authority
- CN
- China
- Prior art keywords
- chitosan oligosaccharide
- added
- present
- oral care
- taken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 19
- 230000037314 wound repair Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 43
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229920001184 polypeptide Polymers 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 239000008213 purified water Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 18
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 18
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 13
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 13
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 239000012620 biological material Substances 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 241000605862 Porphyromonas gingivalis Species 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000001408 fungistatic effect Effects 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 239000013641 positive control Substances 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005548 health behavior Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229960001957 stomatological preparations Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of wound repair and oral care liquid dressing and preparation method thereof, belong to technical field of biological materials, it is to be grouped as by the group of following weight ratio: biological polypeptide 0.05~0.5%, chitosan oligosaccharide: 1~8%, maltodextrin: 0.2~2%, Mint Essence 0.01~0.05%, propylene glycol 0.5~5%, surplus are purified water.Chitosan oligosaccharide and biological polypeptide are all made of the antibacterial principle of physics in the present invention, do not generate drug resistance, and bactericidal range is wide.
Description
Technical field
The present invention relates to technical field of biological materials, in particular to a kind of wound repair and the dressing of oral care liquid and its
Preparation method.
Background technique
Scientific investigations showed that there is up to hundreds of pathogenic bacteria in Human Oral Cavity, these bacteriums are not encroaching on all the time
Each of us oral cavity, life and life and health.Most of oral care product is antibiotic currently on the market, and is resisted
Raw element sterilization has the following: (1) bactericidal range is not wide, can only kill specific bacteria；(2) pathogenic bacteria are not only killed,
Also probiotics can be killed, can not selectivity sterilization；(3) it is difficult to be attached on the surface of a wound, the surface of a wound can not be protected comprehensively；(4)
It is easy that bacterium is made to generate interior pharmacological property, causes the generation of superbacteria.
Summary of the invention
The present invention provides a kind of wound repairs and oral care liquid dressing and preparation method thereof.Solve existing oral cavity shield
Manage product treatment weak curative effect, selectivity sterilization hardly possible, three big difficult points of drug attachment difference.
In order to solve the above technical problems, the technical solution of the present invention is as follows:
A kind of wound repair and oral care liquid dressing, are to be grouped as by the group of following weight ratio: biological polypeptide
0.05~0.5%, chitosan oligosaccharide: 1~8%, maltodextrin: 0.2~2%, Mint Essence 0.01~0.05%, propylene glycol 0.5~
5%, surplus is purified water.
The preparation method of a kind of wound repair and oral care liquid dressing, is prepared by following step:
(1) chitosan oligosaccharide is taken, purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to uniformly mixed, side
Stir side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition
It is completely dissolved to maltodextrin；
(4) propylene glycol is taken, is added in step (3) resulting mixed solution, remaining purified water is added, stirs evenly i.e.
?.
Chitosan oligosaccharide is also known as chitin oligo saccharide, chitooligosaccharide-, is the product obtained by enzymatic isolation method degradation chitosan.It is not only protected
The original characteristic of chitosan has been held, has also added the characteristics such as its dissolubility, moisture retention, inoxidizability, therefore chitosan oligosaccharide has perhaps
Mostly excellent characteristic.First moisture retention: chitosan oligosaccharide has the structure and performance similar with hyaluronic acid, can be used as hyaluronic acid
Substitute be applied to cosmetic field.Second biocidal property: chitosan oligosaccharide can form one layer of cationic reticular membrane on surface of a wound surface,
Bacterium can be prevented to contact with the surface of a wound, have the function that prevention infection and the surface of a wound deteriorate.Third inoxidizability: chitosan oligosaccharide can be inhaled
Ultraviolet light is received, free radical is eliminated, activating cell there are good anti-oxidant, antifatigue, anti-aging effects.4th promotees being cured property: shell is few
Sugar has excellent biocompatibility, and strong environment is provided for dermal cell growth, can be with chemotactic and activated macrophage
Promote neutrophil leucocyte to start agglutination, and growth factor healing acceleration can be traped.5th formability: chitosan oligosaccharide maintains shell
Some characteristics of glycan are easily embarked on journey, it can be with the miscible formation variform of a variety of high-molecular biologics such as: fiber, film, hydrogel.
These features determine that it becomes and prepare the excellent material of Wound dressing.
Biological polypeptide is one kind by glycine, arginine, serine, lysine, leucine, methionine, phenylalanine seven
A kind of small organic molecule of kind Amino acid profile.The molecular formula of biological polypeptide is C in the present invention113H189O35N21S, opposite point
Protonatomic mass: 2341.91.With stronger positive charge, and there is amphiphilic feature.For after the surface of a wound of oral cavity can with it is negatively charged
The bacterium of lotus is combined by electrostatic interaction.The cell membrane of bacterium can be protruded into conjunction with its rear hydrophobic side, punctured cell membrane, made cell
Mass flow goes out, and causes bacterial death.And intraoral most probiotics belong to gram-positive bacteria, cell membrane surface has one layer thicker
Cell wall.The hydrophobic side of polypeptide can not penetrating cell wall, so that probiotics can not be killed.Play the role of selectively sterilizing.Together
When the biological polypeptide synthesis that may also participate in inflammatory reaction, influence cell cycle transitions, promote RNA and DNA, to accelerate impaired
The proliferation and differentiation of skin base cell, can achieve the purpose of rapid wound closure, also have induction capillary plumule shape
At promoting granulation tissue growth, promote damaged skin regeneration, the effects of comprehensive wound repairing.
Beneficial effects of the present invention:
(1) chitosan oligosaccharide and biological polypeptide all have positive charge, and two kinds of biomaterials, which combine, can increase the strong of positive charge
Degree, and it is higher than the superposition amount of the two charge, the electrostatic interaction between pathogenic bacteria is increased, to significantly enhance sterilization effect
Fruit.
(2) chitosan oligosaccharide can form one layer of cationic reticular membrane, while biological polypeptide on surface of a wound surface after acting on the surface of a wound
It can be attached to above chitosan oligosaccharide film, play the role of sustainable protection and wound repairing.
(3) chitosan oligosaccharide and biological polypeptide are all made of the antibacterial principle of physics, so this product does not generate drug resistance, and sterilize
Range is wide.
(4) macaque that biological polypeptide is capable of selectivity kills pathogenic bacteria, protects probiotics, adjusts Oral health behaviours balance, entirely
Nurse oral cavity in face.
(5) chitosan oligosaccharide provides strong environment for dermal cell growth, and biological polypeptide can promote this status of Skin Cell
It splits, grow, the two is assisted mutually, and the healing of the surface of a wound is greatly promoted.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
Some embodiments of invention for those of ordinary skill in the art without creative efforts, can be with
It obtains other drawings based on these drawings.
Inhibitory effect of the present invention to porphyromonas gingivalis in the test of Fig. 1 biocidal property；
Inhibitory effect of the positive control to porphyromonas gingivalis in the test of Fig. 2 biocidal property；
Inhibitory effect of the blank control to porphyromonas gingivalis in the test of Fig. 3 biocidal property；
The inhibitory effect of Fig. 4 present invention, antibiotic and blank control to Bacillus acidi lactici；
Clinical inhibitory effect of Fig. 5 present invention to oral cavity pathogen；
Fig. 6 security and stability tests Detection of Stability result of the present invention.
Specific embodiment
Below in conjunction with the specific embodiment of the invention, technical solution of the present invention is clearly and completely described, is shown
So, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based on the reality in the present invention
Example is applied, every other embodiment obtained by those of ordinary skill in the art without making creative efforts all belongs to
In the scope of protection of the invention.
Embodiment 1
A kind of wound repair and oral care liquid dressing are present embodiments provided, is grouped by the group of following weight ratio
At: biological polypeptide 0.5kg, chitosan oligosaccharide: 2.5kg, maltodextrin: 2kg, Mint Essence: 0.05kg, propylene glycol 0.5kg, purified water
94.45kg。
The preparation method of the present embodiment wound repair and oral care liquid dressing, is prepared by following step:
(1) chitosan oligosaccharide is taken, 76Kg purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to uniformly mixed, side
Stir side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition
It is completely dissolved to maltodextrin；
(4) propylene glycol is taken, is added in step (3) resulting mixed solution, it is quantitative to 100kg with purified water, it stirs evenly
To obtain the final product.
Embodiment 2
A kind of wound repair and oral care liquid dressing are present embodiments provided, is grouped by the group of following weight ratio
At: biological polypeptide 0.3kg, chitosan oligosaccharide: 8kg, maltodextrin: 1kg, Mint Essence 0.03kg, propylene glycol 2kg, purified water
88.67kg。
The present embodiment simultaneously provides the preparation method of the wound repair and oral care liquid dressing, is prepared by following step
It forms:
(1) chitosan oligosaccharide is taken, 73kg purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to uniformly mixed, side
Stir side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition
It is completely dissolved to maltodextrin；
(4) propylene glycol is taken, is added in step (3) resulting mixed solution, it is quantitative to 100kg with purified water, it stirs evenly
To obtain the final product.
Embodiment 3
A kind of wound repair and oral care liquid dressing are present embodiments provided, is grouped by the group of following weight ratio
At: biological polypeptide 0.2kg, chitosan oligosaccharide: 5kg, maltodextrin: 0.5kg, Mint Essence 0.01kg, propylene glycol 3kg, purified water
91.29kg。
The present embodiment simultaneously provides the preparation method of the wound repair and oral care liquid dressing, is prepared by following step
It forms:
(1) chitosan oligosaccharide is taken, 75Kg purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to uniformly mixed, side
Stir side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition
It is completely dissolved to maltodextrin；
(4) propylene glycol is taken, is added in step (3) resulting mixed solution, it is quantitative to 100kg with purified water, it stirs evenly
To obtain the final product.
Embodiment 4
A kind of wound repair and oral care liquid dressing are present embodiments provided, is grouped by the group of following weight ratio
At: biological polypeptide 0.05kg, chitosan oligosaccharide: 1kg, maltodextrin: 0.2kg, Mint Essence 0.02kg, propylene glycol 5kg, purified water
93.63kg。
The present embodiment simultaneously provides the preparation method of the wound repair and oral care liquid dressing, is prepared by following step
It forms:
(1) chitosan oligosaccharide is taken, 75Kg purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to uniformly mixed, side
Stir side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition
It is completely dissolved to maltodextrin；
(4) propylene glycol is taken, is added in step (3) resulting mixed solution, it is quantitative to 100kg with purified water, it stirs evenly
To obtain the final product.
5 present invention of embodiment carries out the experiment of biocidal property bacterium
(oral cavity wound bed fluid dressing) of the invention, positive control (Chlorhexidine), blank control (PBS) are detected respectively to difference
The inhibitory effect of strain.
1. the present invention, positive control and blank control are to the inhibitory effect of porphyromonas gingivalis
Experimental procedure:
(1) activation of strain: porphyromonas gingivalis is inoculated in solid culture case, is activated 24 hours at 37 DEG C.
(2) configuration of culture medium: having configured culture medium according to a certain percentage, and configured culture medium equivalent is uniformly fallen
Enter in three culture dishes, and sequentially adds a certain amount of present invention, positive drug and liquid PBS.
(3) preparation of bacteria suspension: the tested strain after activation is diluted in physiological saline with oese picking lawn
The outstanding bacterium solution that turbidity containing bacterium number is about 0.5Mcf is spare.
(4) culture of strain: a certain amount of outstanding bacterium solution is poured into respectively in ready culture dish, cultivates 18h.
The present invention is as shown in Figure 1 to the inhibitory effect of porphyromonas gingivalis.
Positive control is as shown in Figure 2 to the inhibitory effect of porphyromonas gingivalis.
Blank control is as shown in Figure 3 to the inhibitory effect of porphyromonas gingivalis.
Experimental result: bacterial plaque is stronger more bright fungistatic effect of saving your breath, it can be seen that the present invention is to oral cavity from Fig. 1, Fig. 2, Fig. 3
The inhibiting rate of pathogenic bacteria porphyromonas gingivalis reaches 99%, there is stronger fungistatic effect.
2. the present invention is to the inhibitory effect of other pathogenic bacteria
(1) the certain density present invention is detected to salmonella, staphylococcus aureus, Candida albicans, variation hammer
Sterilizing rate of the pathogenic bacteria such as bacterium, Escherichia coli in two minutes.
Sterilizing rate in 1 present invention of table two minutes
(2) the certain density present invention is detected to salmonella, staphylococcus aureus, Candida albicans, variation hammer
Sterilizing rate of the pathogenic bacteria such as bacterium, Escherichia coli in five minutes.
Sterilizing rate in 2 present invention of table five minutes
Experimental result: as can be seen from Table 1 and Table 2, the fungistatic effect in the present invention two minutes can achieve 95% or more,
Fungistatic effect in five minutes can achieve 99% or more.Illustrate that the present invention imitates most pathogenic bacteria with stronger inhibition
Fruit.
3. the present invention, positive control and blank control are to the inhibitory effect of probiotic lactic acid bacillus
Experimental procedure:
(1) activation of strain: Bacillus acidi lactici is inoculated in solid culture case, is activated 24 hours at 37 DEG C.
(2) preparation of bacteria suspension: the tested strain after activation is diluted in physiological saline with oese picking lawn
The outstanding bacterium solution that turbidity containing bacterium number is about 0.5Mcf is spare.
(3) Bactericidal test: taking the filter paper with a thickness of 3mm, and the circular filter paper piece that production diameter is 6mm is several.Then
The biomaterial of the present invention (No. 1) sterilized, PBS liquid (No. 2), positive control will be immersed respectively after the sterilizing of ready-made filter paper
(No. 3) 30min in drug.Various bacteria suspension 100ul are taken uniformly to be applied to culture medium dish surface, with aseptic nipper by each filter paper
Piece is attached on various plates containing bacterium, is spaced a distance between filter paper.The above operation carries out on the super-clean bench, at 37 DEG C
Culture measures the antibacterial circle diameter of circle filter paper.If bacteriostatic agent is effective, it will appear a sterile life around filter paper
Long transparent circle, i.e. inhibition zone.Using the diameter of inhibition zone as deliberated index, antibacterial circle diameter is bigger, illustrates the bacteriostatic agent pair
Such inhibitory effect for trying bacterium is better, on the contrary then fungistatic effect is poorer.
The present invention, antibiotic and blank control are as shown in Figure 4 to the inhibitory effect of Bacillus acidi lactici bacterium.
Experimental result: from Fig. 4 this it appears that around No. 1 and number filter paper it is unchanged, and have around No. 3 filter paper obvious
Inhibition zone.It can be seen that positive drug has apparent inhibiting effect to probiotic lactic acid bacillus.And the present invention will not inhibit benefit
Raw bacterium growth, can play the role of selectively sterilizing.
6 present invention of embodiment carries out clinical trial:
Clinical research of the present invention is tested in West China stomatological hospital and West China School of Stomatology mouth disease research state key
Room carries out.Test crowd: healthy volunteer 6, one full year of life at age 22-24.The present invention and the positive are used in stipulated time point
Control drug (Chlorhexidine).Respectively detect use before, use the intraoral bacteria containing amount of rear 0h, 4h, 8h.
The present invention is as shown in Figure 5 to the clinical inhibitory effect of oral cavity pathogen.
Experimental result: fungistatic effect of the present invention is stronger as can be seen from Figure 5, sharply using the intracavitary bacteria containing amount of deutostoma of the present invention
It reduces, and the duration is longer, using still there is certain fungistatic effect after 8h.
The security and stability experiment of the invention of embodiment 7:
The present invention is mixed into 10min and 1h with saliva, detects its stability respectively.
Detection of Stability of the present invention is as shown in Figure 6.
Experimental result: from fig. 6, it can be seen that being absorbed as wave crest after 1h with mixing 15min after the present invention and saliva mixing.
Illustrate that this product is not easy to be decomposed by the enzyme in saliva, stability is preferable.
Conclusion
In conclusion the present invention can break oral cavity pathogen comprehensively, fungistatic effect is strong, range is wide, and can protect probiotics, adjust
Oral health behaviours balance is saved, and stability is preferable, the duration is long, can play the role of the total care oral cavity surface of a wound.And energy
Enough prevent trauma surface infestation, wound healing.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Within mind and principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (2)
1. a kind of wound repair and oral care liquid dressing, it is characterised in that be grouped as by the group of following weight ratio: raw
Object polypeptide 0.05~0.5%, chitosan oligosaccharide: 1~8%, maltodextrin: 0.2~2%, Mint Essence 0.01~0.05%, propylene glycol
0.5~5%, surplus is purified water.
2. the preparation method of a kind of wound repair described in claim 1 and oral care liquid dressing, it is characterised in that be by
Following step is prepared:
(1) chitosan oligosaccharide is taken, purified water is added, stirring 30min is completely dissolved to chitosan oligosaccharide, obtains chitosan oligosaccharide solution；
(2) biological polypeptide is taken, is added in chitosan oligosaccharide solution while stirring, 10min is stirred for after addition to being uniformly mixed, side is stirred
Side be added Mint Essence, be stirred for after addition 10min to be uniformly mixed；
(3) maltodextrin is taken, is added in step (2) resulting mixed solution while stirring, continues to stir 30min after addition to wheat
Bud dextrin is completely dissolved；
(4) it takes propylene glycol, is added in step (3) resulting mixed solution, remaining purified water is added, stirs evenly to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810838864.9A CN108969794A (en) | 2018-10-08 | 2018-10-08 | A kind of wound repair and oral care liquid dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810838864.9A CN108969794A (en) | 2018-10-08 | 2018-10-08 | A kind of wound repair and oral care liquid dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108969794A true CN108969794A (en) | 2018-12-11 |
Family
ID=64551772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810838864.9A Pending CN108969794A (en) | 2018-10-08 | 2018-10-08 | A kind of wound repair and oral care liquid dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108969794A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004024024A (en) * | 2002-06-21 | 2004-01-29 | National Food Research Institute | Method for synthesizing glucide or its derivative using polypeptide having functionality participating in chitosan hydrolytic activity by transglycosylation |
| CN101156868A (en) * | 2007-08-29 | 2008-04-09 | 北京海利安生物科技有限公司 | A bacterium-resisting nursing article |
| CN104958778A (en) * | 2015-06-23 | 2015-10-07 | 青岛博益特生物材料股份有限公司 | Antibacterial healing promoting material for oral cavities and application of antibacterial healing promoting material |
| CN107619431A (en) * | 2017-10-11 | 2018-01-23 | 青岛大学附属医院 | A kind of gel polypeptide that can be used for preparing hemostatic material |
| CN108187132A (en) * | 2018-01-05 | 2018-06-22 | 广州润虹医药科技股份有限公司 | A kind of povidone iodine hydrogel antiseptic dressing and preparation method thereof |
-
2018
- 2018-10-08 CN CN201810838864.9A patent/CN108969794A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004024024A (en) * | 2002-06-21 | 2004-01-29 | National Food Research Institute | Method for synthesizing glucide or its derivative using polypeptide having functionality participating in chitosan hydrolytic activity by transglycosylation |
| CN101156868A (en) * | 2007-08-29 | 2008-04-09 | 北京海利安生物科技有限公司 | A bacterium-resisting nursing article |
| CN104958778A (en) * | 2015-06-23 | 2015-10-07 | 青岛博益特生物材料股份有限公司 | Antibacterial healing promoting material for oral cavities and application of antibacterial healing promoting material |
| CN107619431A (en) * | 2017-10-11 | 2018-01-23 | 青岛大学附属医院 | A kind of gel polypeptide that can be used for preparing hemostatic material |
| CN108187132A (en) * | 2018-01-05 | 2018-06-22 | 广州润虹医药科技股份有限公司 | A kind of povidone iodine hydrogel antiseptic dressing and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《食用香精制备技术》: "《食用香精制备技术》", 30 September 2007, 中国纺织出版社 * |
| 陈卫卫等: "《药剂学》", 31 January 2014, 西安交通大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sani et al. | An antimicrobial dental light curable bioadhesive hydrogel for treatment of peri-implant diseases | |
| Mousavi et al. | Antibacterial and antifungal effects of chitosan nanoparticles on tissue conditioners of complete dentures | |
| US9181290B2 (en) | Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D-glucopyranose | |
| ES2758879T3 (en) | Release of viral agents | |
| EP3603654A1 (en) | Prevention and treatment of microbial infections | |
| ES2892961B2 (en) | Biomaterial formed by bacterial cellulose and probiotics and its uses | |
| WO2019169873A1 (en) | Nano antibacterial gel for treating wound infection and promoting healing and preparation method therefor | |
| Rajabnia et al. | Anti-Streptococcus mutans property of a chitosan: Containing resin sealant | |
| Bibire et al. | Biopolymers for surgical applications | |
| Rani et al. | Evaluation of the antibacterial effect of silver nanoparticles on guided tissue regeneration membrane colonization—An in vitro study | |
| Martins et al. | Biocompatibility analysis of chemomechanical caries removal material Papacarie on cultured fibroblasts and subcutaneous tissue | |
| CN110078794B (en) | Antibacterial peptide and application thereof | |
| CN107412256A (en) | Disease is treated with poly- N acetyl glucosamines nanofiber | |
| Chen et al. | A novel wound dressing based on a gold nanoparticle self-assembled hydrogel to promote wound healing | |
| CN113476611A (en) | A composition with skin repairing effect | |
| CN108969794A (en) | A kind of wound repair and oral care liquid dressing and preparation method thereof | |
| Dan et al. | Synergistic approach of graphene oxide-silver-titanium nanocomposite film in oral and dental studies: A new paradigm of infection control in dentistry | |
| CN109875762A (en) | A kind of novel antibacterial adhesive bandage and the preparation method and application thereof | |
| Senel et al. | Application of Chitosan Based Scaffolds for Drug Delivery and Tissue | |
| CN103721248A (en) | Chitosan oral mucosa ulcer patch | |
| Morganti et al. | Chitin Nanofibril: A Natural Eco-Friendly and immunoadjuvant active carrier for medical use | |
| Chen et al. | A Biomimetic Smart Nanoplatform as “Inflammation Scavenger” for Regenerative Therapy of Periodontal Tissue | |
| Chen et al. | Cerium oxide nanoparticles in wound care: a review of mechanisms and therapeutic applications | |
| CN105726386B (en) | A kind of toothpaste for preventing plaque | |
| BR102017022237A2 (en) | ORAL REPAIR BANDAGES, PROCESS OF OBTAINING THEM AND USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181211 |